Australian Clinical Labs Management

Management Kriterienprüfungen 3/4

Australian Clinical Labs CEO ist Melinda McGrath , ernannt in Dec 2020, hat eine Amtszeit von 3.92 Jahren. Die jährliche Gesamtvergütung beträgt A$1.56M , bestehend aus 55.9% Gehalt und 44.1% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 1.09% der Aktien des Unternehmens, im Wert von A$7.76M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 5.4 Jahre bzw. 3.6 Jahre.

Wichtige Informationen

Melinda McGrath

Geschäftsführender

AU$1.6m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	55.9%
Amtszeit als Geschäftsführer	3.9yrs
Eigentum des Geschäftsführers	1.1%
Durchschnittliche Amtszeit des Managements	5.4yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	3.6yrs

Jüngste Management Updates

Recent updates

Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge

Sep 03

Here's Why We Think Australian Clinical Labs (ASX:ACL) Might Deserve Your Attention Today

Aug 14

Australian Clinical Labs Limited (ASX:ACL) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Feb 25

New Forecasts: Here's What Analysts Think The Future Holds For Australian Clinical Labs Limited (ASX:ACL)

Dec 22

The Market Lifts Australian Clinical Labs Limited (ASX:ACL) Shares 31% But It Can Do More

Dec 21

The Strong Earnings Posted By Australian Clinical Labs (ASX:ACL) Are A Good Indication Of The Strength Of The Business

Sep 01

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Melinda McGrath im Vergleich zu den Einnahmen von Australian Clinical Labs verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Jun 30 2024	AU$2m	AU$873k	AU$24m
Mar 31 2024	n/a	n/a	AU$20m
Dec 31 2023	n/a	n/a	AU$15m
Sep 30 2023	n/a	n/a	AU$26m
Jun 30 2023	AU$1m	AU$873k	AU$36m
Mar 31 2023	n/a	n/a	AU$55m
Dec 31 2022	n/a	n/a	AU$73m
Sep 30 2022	n/a	n/a	AU$126m
Jun 30 2022	AU$2m	AU$873k	AU$178m
Mar 31 2022	n/a	n/a	AU$156m
Dec 31 2021	n/a	n/a	AU$134m
Sep 30 2021	n/a	n/a	AU$97m
Jun 30 2021	AU$2m	AU$875k	AU$60m
Mar 31 2021	n/a	n/a	AU$79m
Dec 31 2020	n/a	n/a	AU$98m
Sep 30 2020	n/a	n/a	AU$70m
Jun 30 2020	AU$2m	AU$852k	AU$41m

Vergütung im Vergleich zum Markt: MelindaDie Gesamtvergütung ($USD1.02M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt Australian ($USD875.75K).

Entschädigung vs. Einkommen: MelindaDie Bezüge der Mitarbeiter sind um mehr als 20 % gestiegen, während die Unternehmensgewinne im vergangenen Jahr um mehr als 20 % gesunken sind.

Geschäftsführer

Melinda McGrath

3.9yrs

Amtszeit

AU$1,560,335

Vergütung

Ms. Melinda McGrath is Chief Executive Officer and Executive Director at Australian Clinical Labs Limited since December 19, 2020. She served as Chief Executive Officer and Executive Director at Clinical L...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Melinda McGrath	CEO & Executive Director	3.9yrs	AU$1.56m	1.09% A$ 7.8m
Darren McKee	Chief Executive Officer of Victoria	1.8yrs	AU$37.27k	keine Daten
Matthew Cordingley	Chief Financial Officer	less than a year	keine Daten	keine Daten
Anthony Friedli	Chief Operating Officer	8.8yrs	keine Daten	0% A$ 0
Sean Jackson	Chief Information Officer	9.8yrs	keine Daten	keine Daten
Joe Geran	National Marketing Director	no data	keine Daten	keine Daten
Tony Landgren	National Medical Director & Chief Pathologist	15.8yrs	keine Daten	0% A$ 0
Chris Brownlow	Chief Executive Officer of New South Wales & Australian Capital Territory	13.8yrs	keine Daten	keine Daten
Shae Seymour	Chief Executive Officer of WA/SA/NT	6.8yrs	keine Daten	keine Daten
Eleanor Padman	Company Secretary	3.6yrs	keine Daten	keine Daten
Rob Izzard	Chief Executive Officer of ACL Commercial Pathology	1.8yrs	keine Daten	keine Daten

5.4yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrenes Management: ACLDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (5.4 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Melinda McGrath	CEO & Executive Director	3.9yrs	AU$1.56m	1.09% A$ 7.8m
Michael Alscher	Non-Executive Chairman	1.2yrs	AU$152.73k	0.14% A$ 1.0m
Christine Bartlett	Independent Non-Executive Director	1.3yrs	AU$111.74k	0.010% A$ 71.4k
Leanne Rowe	Independent Non-Executive Director	3.6yrs	AU$131.18k	0.0025% A$ 17.8k
Mark Haberlin	Independent Non-Executive Director	3.6yrs	AU$136.23k	0.024% A$ 169.6k

3.6yrs

Durchschnittliche Betriebszugehörigkeit

61yo

Durchschnittliches Alter

Erfahrener Vorstand: ACLDie Vorstandsmitglieder gelten als erfahren (3.6 Jahre durchschnittliche Amtszeit).

Australian Clinical Labs Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Australian Clinical Labs Limited, Annual General Meeting, Oct 25, 2024

Australian Clinical Labs Limited Announces Appointment of Christine Bartlett as Non-Executive Director

High number of new and inexperienced directors

Independent Non-Executive Director recently sold AU$71k worth of stock

Australian Clinical Labs Limited Announces Resignation of Dr. Michael Stanford as Non-Executive Director

Australian Clinical Labs Limited, Annual General Meeting, Oct 25, 2023

Recent updates

Australian Clinical Labs Limited to Report Fiscal Year 2025 Results on Aug 26, 2025

Investor sentiment improves as stock rises 25%

Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge

Should You Think About Buying Australian Clinical Labs Limited (ASX:ACL) Now?

Final dividend of AU$0.09 announced

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Australian Clinical Labs Limited Provides Financial Guidance for the Fiscal Year 2025

Australian Clinical Labs Limited to Report Fiscal Year 2024 Results on Aug 29, 2024

Australian Clinical Labs Limited, Annual General Meeting, Oct 25, 2024

We Think Australian Clinical Labs (ASX:ACL) Is Taking Some Risk With Its Debt

Upcoming dividend of AU$0.03 per share

Consensus EPS estimates fall by 20%

First half dividend reduced to AU$0.03

First half 2024 earnings released: EPS: AU$0.025 (vs AU$0.13 in 1H 2023)

Are Investors Undervaluing Australian Clinical Labs Limited (ASX:ACL) By 46%?

Australian Clinical Labs Limited to Report First Half, 2024 Results on Feb 28, 2024

Is It Time To Consider Buying Australian Clinical Labs Limited (ASX:ACL)?

Price target decreased by 7.5% to AU$3.56

Upcoming dividend of AU$0.07 per share at 4.6% yield

Consensus EPS estimates fall by 21%

Australian Clinical Labs Limited Announces Appointment of Christine Bartlett as Non-Executive Director

Australian Clinical Labs Limited Declares Full Year Fully Franked Dividend for the Fiscal Year 2023, Payable on 3 October 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of AU$0.07 per share at 13% yield

Price target increased by 7.1% to AU$4.03

First half 2023 earnings released: EPS: AU$0.13 (vs AU$0.65 in 1H 2022)

Australian Clinical Labs Limited Announces Dividend for the Six Months Ended December 31, 2022, Payable on April 26, 2023

Investor sentiment improves as stock rises 16%

Price target decreased by 8.5% to AU$3.76

Price target decreased to AU$4.27

High number of new and inexperienced directors

Price target decreased to AU$4.62

Independent Non-Executive Director recently sold AU$71k worth of stock

Australian Clinical Labs Limited Announces Resignation of Dr. Michael Stanford as Non-Executive Director

Australian Clinical Labs Limited, Annual General Meeting, Oct 25, 2023

Independent Non-Executive Director recently sold AU$140k worth of stock

Upcoming dividend of AU$0.41 per share

Here's Why We Think Australian Clinical Labs (ASX:ACL) Might Deserve Your Attention Today

Full year 2022 earnings: EPS misses analyst expectations

Price target decreased to AU$5.30

Australian Clinical Labs Limited Declares Dividend for the Period of Six Months Ended 30 June 2022

Investor sentiment deteriorated over the past week

CEO & Executive Director recently bought AU$335k worth of stock

High number of new and inexperienced directors

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Australian Clinical Labs Limited Declares Ordinary Dividend for the Period of Six Months December 31, 2021, Payable April 21, 2022

Australian Clinical Labs Limited (ASX:ACL) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Australian Clinical Labs Limited Revises Earnings Guidance for the First Half 2022

New Forecasts: Here's What Analysts Think The Future Holds For Australian Clinical Labs Limited (ASX:ACL)

The Market Lifts Australian Clinical Labs Limited (ASX:ACL) Shares 31% But It Can Do More

Investor sentiment improved over the past week

Consensus EPS estimates increase by 46%

Australian Clinical Labs Limited (ASX:ACL) completed the acquisition of Medlab Pathology Pty Ltd.

Independent Non-Executive Director recently bought AU$99k worth of stock

The Strong Earnings Posted By Australian Clinical Labs (ASX:ACL) Are A Good Indication Of The Strength Of The Business

Full year 2021 earnings released: EPS AU$0.40 (vs AU$0.28 in FY 2020)

Australian Clinical Labs Limited Provides Earnings Guidance for the Fiscal Year of 2021

Australian Clinical Labs Limited has completed an IPO in the amount of AUD 408.559209 million.

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter